Pfizer Holding Its Breath On Exubera DTC Advertising To Focus On Education
Executive Summary
Pfizer will begin direct-to-consumer advertising for its inhaled insulin therapy Exubera approximately one year after its approval, the company said at a June 10 briefing in Washington, D.C
You may also be interested in...
Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta
Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta
Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays
Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20